Human immunodeficiency virus (HIV) infection characterized by profound CD4+ T cell destruction compromised mucosal barrier function and chronic immune activation. In Kingdom of Saudi Arabia (KSA), acquired immune deficiency syndrome (AIDS) considers a significant public health problem. Our study design incorporated sixty-six AIDS Saudi patients under Highly Active Antiretroviral Therapy (HAART1) and after 6-12 months (HAART2), twenty healthy persons as a control. We measure subset lymphocyte cells by flow cytometry, CD3+4+ T cells, CD3+ 8+ T cells, and CD16+/CD56+ ratio were high significantly lower than controls in HARRT1 and HAART2 treatment (P ≤ 0.01). COBAS AmpliPrep assessed quantitation of HIV-1 RNA viral load in plasma, also Screening of Human leukocyte antigens antibodies (Panel reactive antibody (PRA)) measured by Luminex 100. There were no significant differences in class I, class II antibodies under the differences between groups, since the indication level value attained (0.311) Chi-square=4.780, and (0.104) Chi-square=4.531 respectively and these values were greater than (0.05) and inconsiderable. Contrary, the results of Class II showed considerable differences antibodies with variable gender. The level value attained (0.008), for study's Saudi women member. The more Immune-biomedical research will be needed in the future to decrease morbidity and mortality in HIV/AIDS patients.